🇺🇸 FDA
Pipeline program

dupilumab

R668-COPD-2491

Approved small_molecule active

Quick answer

dupilumab for Chronic Obstructive Pulmonary Disease (COPD) is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials